Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DCYV91
|
|||
| Drug Name |
TBA-7371
|
|||
| Synonyms |
1494675-86-3; DprE1-IN-1; AZ7371; N-(2-hydroxyethyl)-1-((6-methoxy-5-methylpyrimidin-4-yl)methyl)-6-methyl-1H-pyrrolo[3,2-b]pyridine-3-carboxamide; UNII-R3T98GBE3C; AZ-7371; R3T98GBE3C; CHEMBL3109802; 1H-Pyrrolo(3,2-b)pyridine-3-carboxamide, N-(2-hydroxyethyl)-1-((6-methoxy-5-methyl-4-pyrimidinyl)methyl)-6-methyl-; 1H-Pyrrolo[3,2-b]pyridine-3-carboxamide, N-(2-hydroxyethyl)-1-[(6-methoxy-5-methyl-4-pyrimidinyl)methyl]-6-methyl-; ZA7371; AZ-7371DprE1-IN-1; AZ7371;DprE1-IN-1; SCHEMBL16395186; EX-A777; BCP16818; BDBM50019654; MFCD29477419; ZINC103248024; CS-5414; ZA-7371; HY-19750; FT-0700212; J-690193; N-(2-Hydroxyethyl)-1-((6-methoxy-5-methylpyrimidin-4-yl)methyl)-6- methyl-1H-pyrrolo(3,2-b)pyridine-3-carboxamide; N-(2-hydroxyethyl)-1-[(6-methoxy-5-methyl-pyrimidin-4-yl)methyl]-6-methyl-pyrrolo[3,2-b]pyridine-3-carboxamide; N-(2-hydroxyethyl)-1-[(6-methoxy-5-methylpyrimidin-4-yl)methyl]-6-methylpyrrolo[3,2-b]pyridine-3-carboxamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Tuberculosis [ICD-11: 1B10-1B14] | Phase 2 | [1] | |
| Company |
TB Alliance
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H21N5O3
|
|||
| Canonical SMILES |
CC1=CC2=C(C(=CN2CC3=C(C(=NC=N3)OC)C)C(=O)NCCO)N=C1
|
|||
| InChI |
1S/C18H21N5O3/c1-11-6-15-16(20-7-11)13(17(25)19-4-5-24)8-23(15)9-14-12(2)18(26-3)22-10-21-14/h6-8,10,24H,4-5,9H2,1-3H3,(H,19,25)
|
|||
| InChIKey |
VDRYGTNDKXIPSK-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1494675-86-3
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Mycobacterium Decaprenylphosphoryl-beta-D-ribose oxidase (McyB dprE1) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03199339) A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of TB Alliance. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.